Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_0067 |
| Primary information | |
|---|---|
| B3PDB ID | b3pdb_0067 |
| Peptide Name | HAVN2 |
| PEPTIDE SEQUENCE (1-letter) | SHAVS |
| PEPTIDE SEQUENCE (3-letter) | SerHisAlaValSer |
| N-terminal modification | NA |
| C-terminal modification | NA |
| Chemical modification | NA |
| Peptide Length | 5 |
| Conformation | Cyclic |
| Peptide Nature | NA |
| Source/Origin of peptide | Chemically synthesized |
| SMILES | N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CO)C(=O)O |
| Cell Line | NA |
| In vitro CONCENTRATION | NA |
| In vitro METHOD | NA |
| In vitro RESULT | NA |
| ANIMAL MODEL | C57BL6 mice |
| In vivo CONCENTRATION | NA |
| In vivo MODE OF DELIVERY | Intracerebral ventricular |
| In vivo METHOD | Mass Spectromtery |
| In vivo RESULT | It is able to deliver an IRdye800CW-labeled IgG monoclonal antibody into the brain. |
| ACTION | Synthesized novel cyclic peptides are able efectively modulate the BBB to enhance the delivery of mA |
| TRANSPORT TYPE | NA |
| SUBCELLULAR LOCALISATION | NA |
| COMBINATION | Combined with monoclonal antibody |
| PHYSICAL CONDITION | NA |
| RESPONSE | NA |
| RESULT | NA |
| LABEL | NA |
| PMID | 31683745 |